Japanese health ministry approves Merck & Eisais Keytruda plus Lenvima for radically unresectable or metastatic RCC

Merck, known as MSD outside the United States and Canada, and Eisai announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of Keytruda, Merck